Terguride
![]() |
|
Systematic (IUPAC) name | |
---|---|
N,N-diethyl-N'-[(8α)-6-methylergolin-8-yl]urea
|
|
Clinical data | |
AHFS/Drugs.com | International Drug Names |
Legal status |
|
Routes of administration |
Oral |
Identifiers | |
CAS Number | 37686-84-3 |
ATC code | G02CB06 (WHO) |
PubChem | CID: 443951 |
IUPHAR/BPS | 56 |
ChemSpider | 392004 |
UNII | 21OJT43Q88 ![]() |
KEGG | D01348 ![]() |
Chemical data | |
Formula | C20H28N4O |
Molecular mass | 340.46 g/mol |
|
|
|
|
(verify) |
Terguride (INN) is a serotonin antagonist. It is used for the treatment of hyperprolactinemia. Terguride is an oral, potent antagonist of 5-HT2B and 5-HT2A (serotonin) receptors. Serotonin stimulates the proliferation of pulmonary artery smooth muscle cells, and induces fibrosis in the wall of pulmonary arteries. Together, this causes vascular remodeling and narrowing of the pulmonary arteries. These changes result in increased vascular resistance and PAH. Due to the potential anti-proliferative and anti-fibrotic activity of terguride, this potential medicine could offer the hope of achieving reversal of pulmonary artery vascular remodeling and attenuation of disease progression.[1]
In May 2008, terguride was granted orphan drug status for the treatment of pulmonary arterial hypertension.[2] In May 2010 Pfizer purchased world-wide rights for the drug.[3]
References
<templatestyles src="Reflist/styles.css" />
Cite error: Invalid <references>
tag; parameter "group" is allowed only.
<references />
, or <references group="..." />
<templatestyles src="Asbox/styles.css"></templatestyles>
- ↑ Janssen W, Schymura Y, Novoyatleva T, Kojonazarov B, Boehm M, Wietelmann A, Luitel H, Murmann K, Krompiec DR, Tretyn A, Pullamsetti SS, Weissmann N, Seeger W, Ghofrani HA, Schermuly RT. 5-HT2B Receptor Antagonists Inhibit Fibrosis and Protect from RV Heart Failure. Biomed Research International. 2015;2015:438403. doi 10.1155/2015/438403 PMID 25667920
- ↑ Presseportal (Swiss press portal, in German)
- ↑ TheDay.com 5/10/2010
- Pages with reference errors
- Drugs with non-standard legal status
- Chemical articles having calculated molecular weight overwritten
- Infobox drug articles without a structure image
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Dopamine agonists
- Orphan drugs
- Ureas
- Genito-urinary system drug stubs